Chan‐Young Ock

University of Seoul — South Korea

Medicine · Health Sciences

22h-index2.0kcitations369works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(174), Head and Neck Cancer Studies(93), Colorectal and Anal Carcinomas(81), Radiomics and Machine Learning in Medical Imaging(79), Cancer Genomics and Diagnostics(64)

Publications368 total

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy
npj Precision Oncology·2025Open Access
Table 2 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Table S1 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S6 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S3 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
2025Open Access
Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Cancer Research Communications·2025· 1 citedOpen Access
1098 Unveiling spatial correlation between cell surface targets and lymphocytes via artificial intelligence (AI)-powered quantitative immunohistochemistry (IHC) analysis
Regular and Young Investigator Award Abstracts·2025Open Access
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin
JCO Precision Oncology·2025· 1 citedOpen Access
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
ESMO Open·2025Open Access
Translating clinical gene sequencing into a foundational representation of tumor subtype
2025Open Access
Supplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S1 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S7 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S5 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S18 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
page 1 of 19Next →

Frequent Co-authors

Bhumsuk Keam(14), Kyunghyun Paeng(12), Seonwook Park(10), Tae Min Kim(10), Minuk Ma(9), Se‐Hoon Lee(9), Soo Ick Cho(9), Dae Seog Heo(9), Seokhwi Kim(8), Sérgio Pereira(7), Changhee Park(7), Dong‐Wan Kim(7), Yoojoo Lim(7), Gahee Park(7), Sangjoon Choi(6), Wonkyung Jung(6), Hyojin Kim(5), Miso Kim(5), Sehhoon Park(4), Se Hyun Kim(4)